Email this article 
Post a Comment 
Evaluation of surface dose outside the treatment area for five breast cancer irradiation modalities using thermo-luminescent dosimeters
Abstract
Purpose: To measure and compare the surface dose outside the treatment area at six different points of interest (POIs) for five different breast cancer radiation treatment modalities by using thermo-luminescent dosimeters (TLDs). This experiment will evaluate the magnitude of the dose due to scatter and leakage radiation at different areas outside the target on a patient that could potentially lead, in the long term, to radiation induced secondary malignancies.
Methods: TLD-100 were calibrated according to the University of Wisconsin Radiation Calibration Laboratory protocol and then used for dose measurements at selected POIs namely sternum, lower abdomen, contralateral breast, thyroid, shoulder, and eye. Twenty five breast cancer patients and the following modalities were included in this study: Strut-adjusted volume implant (SAVI), mammosite multi-lumen (ML), Accuboost, electron boost and photon boost. The surface doses in all patients were measured in a single fraction. The delivered target doses were normalized to 200 cGy. Finally, breast quadrant analysis was performed.
Results: The maximum average dose for each POI was as follows: Sternum 6.51 cGy (SD 2.93), lower abdomen 4.50 cGy (SD 2.63), contralateral breast 8.52 cGy (SD 3.86), thyroid 5.50 cGy (SD 2.75), shoulder 5.58 cGy (SD 2.77), and eye 2.65 cGy (SD 0.68). The highest POI dose of 15.84 cGy was found in contralateral breast.
Conclusion: The measured surface dose at each POI varies with the modality of treatment. The surface doses show a strong correlation to the tumor bed location in the breast quadrant. The SAVI, electron boost, and photon boost modalities had delivered smaller surface dose at POIs than the Accuboost and Mammosite ML modalities. While the measured doses fall within the low range, its significance in producing second malignancies would require a large cohort of patients and a longer follow up.
Keywords
Full Text:
PDFReferences
Spear SL, Prada CA. Reduction mammaplasty in conjunction with breast conservation. Semin Plast Surg 2004; 18:255-60.
American Cancer Society Intermural research. Cancer treatment and survivorship facts and figures 2012-2013.
Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68:99-112.
Schneider U. Modeling the Risk of Secondary Malignancies after Radiotherapy. Genes 2011; 2:1033-49.
Taylor ML, Kron T. Consideration of the radiation dose delivered away from the treatment field to patients in radiotherapy. J Med Phys 2011; 36:59-71.
International Commission for Radiation Protection. Low-dose extrapolation of radiation-related cancer risk. ICRP Publication 99 Ann; 2005.
Committee on the biological effects of ionizing radiation. Health risks from exposure to low levels of ionizing radiation. Washington DC, National Research Council, National Academy Press; 2006.
Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007; 106:439-51.
Suit H, Goldberg S, Niemierko A, et al. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res 2007; 167:12-42.
Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. JNCI J Natl Cancer Inst 2012; 104:357-70.
Boice JD Jr, Day NE, Andersen A, et al. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985; 74:955-75.
Raymond JS, Hogue CJ. Multiple primary tumors in women following breast cancer, 1973-2000. Br J Cancer 2006; 94:1745-50.
Roychoudhuri R, Evans H, Robinson D, Møller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004; 91:868-72.
Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88:398-406.
Neugut AI, Robinson E, Lee WC, et al. Lung cancer after radiation therapy for breast cancer. Cancer 1993; 71:3054-7.
Ron E. Cancer risks from medical radiation. Health Phys 2003; 85:47-59.
Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:406-14.
Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001; 51:679-90.
Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006; 118:2285-92.
van der Giessen PH, Hurkmans CW. Calculation and measurement of the dose to points outside the primary beam for CO-60 gamma radiation. Int J Radiat Oncol Biol Phys 1993; 27:717-24.
Doll R, Wakeford R. Risk of childhood cancer from fetal irradiation. Br J Radiol 1997; 70:130-9.
Sandeman TF. The effects of x irradiation on male human fertility. Br J Radiol 1966; 39:901-7.
Lee N, Chuang C, Quivey JM, et al. Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2002; 53:630-7.
Benedick AF, Jan Van DG. Peripheral dose from megavoltage beams. Med Phys 1983; 10:809-17.
Jereczek-Fossa BA, Alterio D, Jassem J, et al. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004; 30:369-84.
International Commission on Radiological Protection. Nonstochastic Effects of Ionizing Radiation. ICRP Publication 41 Ann ICRP 1984; 14.
Diallo I, Haddy N, Adjadj E, et al. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys 2009; 74:876-83.
Welte B, Suhr P, Bottke D, et al. Second malignancies in high‑dose areas of previous tumor radiotherapy. Strahlenther Onkol 2010; 186:174-9.
Stovall M, Blackwell CR, Cundiff J, et al. Fetal dose from radiotherapy with photon beams: report of AAPM Radiation Therapy Committee Task Group No. 36. Med Phys 1995; 22:63-82.
Berris T, Mazonakis M, Stratakis J, et al. Calculation of organ doses from breast cancer radiotherapy: a Monte Carlo study. J Appl Clin Med Phys 2013; 14:4029.
Stovall M, Smith SA, Langholz BM, et al. Dose to the contra-lateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 2008; 72:1021-30.
Harrison RM, Wilkinson M, Rawlings DJ, Moore M. Doses to critical organs following radiotherapy and concomitant imaging of the larynx and breast. Br J Radiol 2007; 80:989-95.
Berrington de GA, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer patients. Br J Cancer 2010; 102:220-26.
Joosten A, Matzinger O, Jeanneret-Sozzi W, et al. Evaluation of organ-specific peripheral doses after 2-dimensional, 3-dimensional and hybrid intensity modulated radiation therapy for breast cancer based on Monte Carlo and convolution/ superposition algorithms: implications for secondary cancer risk assessment. Radiother Oncol 2013; 106:33-41.
Raffi JA, Davis SD, Hammer CG, et al. Determination of exit skin dose for 192Ir intracavitary accelerated partial breast irradiation with thermoluminescent dosimeters. Med Phys 2010; 37: 2693-702.
Kinhikar R, Gamre P, Tambe C, et al Peripheral dose measurements with diode and thermoluminescence dosimeters for intensity modulated radiotherapy delivered with conventional and un-conventional linear accelerator. J Med Phys 2013; 38:4-8.
Manoharan SR, Rodriguez RR, Bobba VS, et al. Dosimetry evaluation of SAVI-based HDR brachytherapy for partial breast irradiation. J Med Phys 2010; 35:131-6.
Bloom ES, Kirsner S, Mason BE, et al. Accelerated partial breast irradiation using the strut-adjusted volume implant single-entry hybrid catheter in brachytherapy for breast cancer in the setting of breast augmentation. Brachytherapy 2011; 10:178-83.
Dickler A, Kirk M, Choo J, et al. Treatment volume and dose optimization of MammoSite breast brachytherapy applicator. Int J Radiat Oncol Biol Phys 2004; 59:469-74.
Hepel JT, Wazer DE. A comparison of brachytherapy techniques for partial breast irradiation. Brachytherapy 2012; 11:163-75.
Rivard MJ, Melhus CS, Wazer DE, Bricault RJ Jr. Dosimetric characterization of round HDR 192Ir Accuboost applicators for breast brachytherapy. Med Phys 2009; 36:5027-32.
Romestaig P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997; 15:963-8.
Kovacs A, Hadjiev J, Lakosi F, et al. Comparison of photon with electron boost in treatment of early stage breast cancer. Pathol Oncol Res 2008; 14:193-7.
Toscas JI, Linero D, Rubio I, et al. Boosting the tumor bed from deep-seated tumors in early-stage breast cancer: a planning study between electron, photon, and proton beams. Radiother Oncol 2010; 96:192-8.
Nunn AA, Davis SD, Micka JA, DeWerd LA. LiF:Mg,Ti TLD response as a function of photon energy for moderately filtered x-ray spectra in the range of 20-250 kVp relative to 60Co. Med Phys 2008; 35:1859-69.
Mobit PN, Nahum AE, Mayles P. The energy correction factor of LiF thermoluminescent dosemeters in megavoltage electron beams: Monte Carlo simulations and experiments. Phys Med Biol 1996; 41:979-93.
Maiello ML, Gulbin JF, Planque GD, Heaton HT. International Mini-intercomparision investigating an under response of TLDs calibrated with 137Cs. Radiat Prot Dosimetry 1990; 34:175-8.
McKinlay AF. Thermo-luminescence dosimetry medical physics handbooks 5, Adam Hilger Ltd; 1981:34-35.
DOI: http://dx.doi.org/10.14319/ijcto.0301.17
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.
Number of visits since October, 2013